Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in APOL1 Associated Kidney Disease
NCT05237388Phase 2Completed
- Sponsor
- Duke University
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in focal segmental glomerulosclerosis (FSGS), chronic kidney disease (CKD), sponsored by Duke University. Started Apr 2023; status: completed.
02
Drugs
baricitinib
03
Conditions
focal segmental glomerulosclerosis (FSGS)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05237388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05237388.